IBD-Associated Arthritis

Top Story

Direct-to-consumer genetic testing not ready for prime time in rheumatology

Direct-to-consumer genetic testing not ready for prime time in rheumatology
January 18, 2019
In the Journals

Reverse switch from biosimilar to Remicade produces similar IBD outcomes

January 14, 2019
Patients with inflammatory bowel disease who switched from biosimilar infliximab to Remicade experienced similar results regarding remission, trough levels and antibody…
Meeting NewsVideo

VIDEO: Rheumatologic, autoimmune disease can be hard to diagnose in patients with IBD

December 21, 2018
ORLANDO — In this exclusive video from Advances in IBD 2018, Raymond Cross, MD, MS, director of the inflammatory bowel disease program at the University of…
In the JournalsPerspective

More than half of arthritis patients aged 45 or older untreated

October 16, 2018
More than 50% of adults aged 45 years or older with some form of arthritis are currently going untreated, despite a substantial proportion experiencing severe symptoms…
More Headlines »

Rheum360: Focus on Biosimilars

This activity is supported by an independent medical education grant from Sandoz Inc., a Novartis Division.

Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, vasculitis, and axial…
More »
Meeting News

VIDEO: Speaker reviews factors that impact response to treatment for Crohn’s disease, ulcerative colitis

March 28, 2017
More »

Ace the Case: A 52-Year-Old Patient With Rheumatoid Arthritis Who Had an Inadequate Response to Methotrexate and a Tumor Necrosis Factor Inhibitor

There is no commercial support for this activity.

This educational activity will utilize a case study to discuss the management of a 52-year-old patient with rheumatoid…
More »